共 12 条
[1]
Efficacyandsafetyofaspe鄄cificinhibitoroftheBCR-ABLtyrosinekinaseinchronicmyeloidleukemia. DrukerBJ,TalpazM,RestaDJ etal. NEnglJMed熏 . 2001
[2]
Involvementofplatelet-derivedgrowthfactorindisease押developmentofspecificantagonists. OstmanA,HeldinCH. AdvCancerRes . 2001
[3]
Temozolomideenhancesherpessimplexvirushymidinekinase/ganciclovirtherapyofma鄄lignantglioma. RainovNG,FelsC,DroegeJW etal. CancerGeneTher . 2001
[4]
Theselectivetyrosineki鄄naseinhibitorSTI571inhibitssmallcelllungcancergrowth. KrystalGW,HonsawekS,LitzJ etal. ClinCancerRes . 2000
[5]
InhibitionofPlatelet-de鄄rivedGrowthFactor-mediatedProliferationofOsteosarcomaCellsbytheNovelTyrosineKinaseInhibitorSTI571. McGaryEC,WeberK,MillsL etal. ClinCancerRes . 2002
[6]
Platelet derivedgrowthfactoranditsreceptorsinhumanastrocytomaoperationspecimenssupportstheex istenceofanautocrineloop. GuhaA,DashnerK,BlackPM,etal. International Journal of Cancer . 1995
[7]
Intracranialinhibitionofplatelet-derivedgrowthfactor-mediatedglioblastomacellgrowthbyanorallyactivekinaseinhibitorofthe2-pheny-laminopyrimidineclass犤J犦. KilicT,AlbertaJA,ZdunekPR,etal. Cancer Research . 2000
[8]
Safetyandefficacyofimatinib(STI571)inmetasta ticgastrointestinalstromaltumors:aphaselstudy. VanOosteromAT,JudsonI,Verweij J,etal. The Lancet . 2001
[9]
Imatinibmesylate-aneworaltargetedtherapy. SavageDG,AntmanKH. The New England Journal of Medicine .
[10]
Pharmacologyofimatinib穴STI571. BuchdungerE,O’’ReillyT,WoodJ. European Journal of Cancer . 2002